Icaritin inhibits PD‐L1 expression by Targeting Protein IκB Kinase α

Icaritin, a small molecule currently being investigated in phase III clinical trials in China (NCT03236636 and NCT03236649) for treatment of advanced hepatocellular carcinoma (HCC), is a prenylflavonoid derivative obtained from the Epimedium genus. Previously, it was found that Icaritin decreased th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Dongliang, Zhu, Hai, Wang, Jun, Hao, Haibang, Guo, Yuming, Wang, Jiaojiao, Han, Xu, Zou, Liangfeng, Li, Zhongwan, Yao, Hua, Zhu, Jinsong, Zhou, Junma, Peng, Yong, Li, Jian, Meng, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Immunomodulation and immune therapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248075/
https://www.ncbi.nlm.nih.gov/pubmed/33354776
http://dx.doi.org/10.1002/eji.202048905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248075/
https://www.ncbi.nlm.nih.gov/pubmed/33354776
http://dx.doi.org/10.1002/eji.202048905

Ejemplares similares